home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Software Vault: The Sapphire Collection
/
Software Vault (Sapphire Collection) (Digital Impact).ISO
/
cdr16
/
med9410d.zip
/
M94A0701.TXT
< prev
next >
Wrap
Text File
|
1994-10-21
|
2KB
|
33 lines
Document 0701
DOCN M94A0701
TI Acetylation phenotype and hypersensitivity (HS) to
trimethoprim-sulphamethoxazole (TMP-SMX) in HIV-infected patients.
DT 9412
AU Carr A; Gross A; Cooper DA; Centre for Immunology, St. Vincent's
Hospital.
SO Annu Conf Australas Soc HIV Med. 1993 Oct 28-30;5:31 (abstract no.
TC11). Unique Identifier : AIDSLINE ASHM5/94348954
AB AIMS: HS to TMP-SMX is more common in patients with HIV infection. In
those without HIV infection, HS is more common in those with a slow
acetylator phenotype. A study was conducted to determine if the slow
acetylation phenotype is associated with an increased risk of HS to
TMP-SMX in patients with HIV. METHODS: Acetylation phenotype was
determined by measuring the ratio of two urinary caffeine metabolites,
5-acetylamino-6-amino-3-methyl uracil and 1-methyl xanthine after
ingestion of a single 200 mg dose of caffeine. RESULTS: Of the 28
subjects, 20 (71%) expressed a slow acetylation phenotype and 8 (29%) a
fast phenotype. Of the 16 subjects with prior HS, 15 (94%) had a slow
acetylation phenotype, versus 5 (42%) of 12 subjects with a fast
phenotype (P < 0.01). CONCLUSIONS: HIV-infected subjects have an
increased prevalence of the slow acetylation phenotype. A slow
acetylation phenotype correlates with a history of HS to TMP-SMX.
DE Acetylation Caffeine/DIAGNOSTIC USE/PHARMACOKINETICS Drug
Hypersensitivity/*GENETICS Human HIV Infections/*DRUG THERAPY/GENETICS
*Phenotype Risk Factors Trimethoprim-Sulfamethoxazole
Combination/*ADVERSE EFFECTS/ PHARMACOKINETICS/THERAPEUTIC USE MEETING
ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).